ALDH1 inhib 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 


12345678910111213...1314»
  • ||||||||||  albumin-bound paclitaxel / Generic mfg.
    Utilizing nature tropism of a novel nanomaterial towards cancer stem cells | Poster Board #M12 (In-person; Poster Board #M12; Studio 3 - 10 (New Orleans Marriott)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_11502;    
    In conclusion, these findings suggest that PRMT1 and its inhibitor, furamidine, are potential novel therapeutic targets and drug candidates for effectively suppressing GSC growth. When chemotherapeutic agent, paclitaxel (PTX), was encapsulated in the P 2 NPs (PTX-P 2 ), the delivery efficiency of PTX to the MDA-MB-231 cells was significantly improved when compared with PTX-P 1 and Abraxane
  • ||||||||||  Journal, Cancer stem:  The role of telocytes and miR-21-5p in tumorigenicity and metastasis of breast cancer stem cells. (Pubmed Central) -  Mar 6, 2024   
    Taken together, these results indicate that limonin is a promising compound that targets CSCs and could be used to combat CRC recurrence and metastasis. In our study, by gene/protein level analysis we demonstrated that telocytes may have the potential to reduce cancer metastasis through miR-21-5p in breast cancer progression and reduce EMT transition.
  • ||||||||||  Journal:  Development of substituted benzimidazoles as inhibitors of human aldehyde dehydrogenase 1A isoenzymes. (Pubmed Central) -  Mar 6, 2024   
    Optimization of the CM10 scaffold, aided by ALDH1A1 crystal structures, led to improved biochemical potencies, improved cellular efficacy as demonstrated by reduction in ALDEFLUOR signal in HGSOC cells, and substantial improvements in liver microsomal stability. Based on this work we identified two compounds 17 and 25 suitable for future in vivo proof of concept experiments.
  • ||||||||||  FOSL1 promotes glioma tumorigenesis and stemness through NF-?B and STAT3 pathways (Section 6) -  Mar 5, 2024 - Abstract #AACR2024AACR_8571;    
    Based on this work we identified two compounds 17 and 25 suitable for future in vivo proof of concept experiments. The FOSL1 molecular pathway is functionally connected to NF-?B and STAT3 activation, enhances stemness, and FOSL1 is a novel GBM drug target.
  • ||||||||||  Developing a novel humanized anti-FABP4 antibody for breast cancer treatment (Section 25) -  Mar 5, 2024 - Abstract #AACR2024AACR_8035;    
    Notably, the humanized variant, 12G2-variant 9 (12G2-vt9), effectively inhibited mammary tumor growth and progression by reducing the activity of FABP4/ALDH1 in different breast cancer mouse models. Our findings suggest that 12G2-Vt9 is a promising neutralizing mAb targeting FABP4-mediated cancer stemness through ALDH1 signaling, offering potential as a targeted therapeutic antibody for the clinical treatment of breast cancer.
  • ||||||||||  AZD5991 / AstraZeneca, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
    Combined inhibition of MCL-1 and MEK reduces tumor growth in a triple-negative/inflammatory breast cancer, MEK-resistant xenograft mouse model (Section 27) -  Mar 5, 2024 - Abstract #AACR2024AACR_6791;    
    Further, we treated resistant cells with MEKi AZD6244 and an MCL-1i (AZD5991) that confirmed restoration of MEK sensitivity in both resistant cell lines, resulting in decreased cell viability, colony formation and increased apoptosis. Our results suggest that MCL-1 is important for inducing acquired MEK resistance and combining an MCL-1i with a MEKi could improve treatment outcomes of patients with TNBC or IBC who have developed resistance to single-agent MEKi.
  • ||||||||||  tamoxifen / Generic mfg.
    The impact of tamoxifen on autophagic and epigenetic regulation in endometrial cancer (Section 41) -  Mar 5, 2024 - Abstract #AACR2024AACR_2386;    
    Our findings demonstrate tamoxifen's influence on cellular and molecular pathways, highlighting the complex interplay between drug treatment and cancer progression. The observed epigenetic changes provide insight into the mechanisms by which tamoxifen may contribute to endometrial cancer risk, suggesting potential targets for therapeutic intervention.
  • ||||||||||  pracinostat (SB939) / Helsinn, MEI, Menarini
    Journal:  ALDH1A3 contributes to tumorigenesis in high-grade serous ovarian cancer by epigenetic modification. (Pubmed Central) -  Mar 4, 2024   
    CHIP assay demonstrated a significant enrichment of H3K27ac at the PITX1 promoter, and ALDH1A3 knockdown reduced the binding between H3K27ac and PITX1. Taken together, our data suggest that ALDH1A3, transcriptional activated by HIF-1?, promotes tumorigenesis and decreases chemosensitivity by increasing H3K27ac of PITX1 promoter in HGSOC.
  • ||||||||||  cisplatin / Generic mfg., epirubicin / Generic mfg.
    Preclinical, Journal:  Non-mitotic proliferation of malignant cancer cells revealed through live-cell imaging of primary and cell-line cultures. (Pubmed Central) -  Feb 11, 2024   
    Moreover, reversible transitions through the three modes of proliferation, i.e., mitosis, abnormal mitosis and non-mitosis, were observed when anticancer drug concentrations were grossly increased inducing non-mitosis or decreased favoring mitosis. Potential clinical significance of non-mitotic proliferation in cancer drug resistance and recurrence, and its relationship with cancer stem cells are worthy of further studies.
  • ||||||||||  Journal, Cancer stem:  MACC1 Regulates LGR5 to Promote Cancer Stem Cell Properties in Colorectal Cancer. (Pubmed Central) -  Feb 10, 2024   
    Taken together, this study indicates that the metastasis inducer MACC1 acts as a cancer stem cell-associated marker. Interventional approaches targeting MACC1 would potentially improve further targeted therapies for colorectal cancer patients to eradicate CSCs and prevent cancer recurrence and distant metastasis formation.
  • ||||||||||  Journal, Cancer stem:  Combining microfluidic chip and low-attachment culture devices to isolate oral cancer stem cells. (Pubmed Central) -  Feb 2, 2024   
    This study demonstrates the effectiveness of the microfluidic chip-based approach in isolating oral cancer cell clones with elevated stem-like characteristics. This method offers a valuable tool for further investigation of CSCs and their role in cancer progression, as well as future therapy development for oral cancers.
  • ||||||||||  Journal:  Gut microbiome mediates ferroptosis resistance for colorectal cancer development. (Pubmed Central) -  Jan 26, 2024   
    Significantly, P. anaerobius is enriched in CRC patients, and supplementing IDA or P. anaerobius accelerates CRC progression in spontaneous or orthotopic mouse models. Taken together, these findings suggest that targeting P. anaerobius-mediated ferroptosis resistance emerges as a promising strategy to combat CRC development.
  • ||||||||||  Journal:  The prognostic value of stem cell markers in triple-negative breast cancer. (Pubmed Central) -  Jan 12, 2024   
    In the multivariate analysis including all of the examined clinicopathological data and markers, only CD117 showed a statistical impact on OS. We failed to demonstrate a prognostic impact for most stem cell markers tested in triple-negative breast cancer, but lack of ALDH1 staining and CD44 expression appears as of prognostic value, requiring further examination in independent studies.
  • ||||||||||  Review, Journal, Cancer stem:  The Role of Cancer Stem Cell Markers in Ovarian Cancer. (Pubmed Central) -  Jan 11, 2024   
    Some markers expressed on the surface of CSCs correlate with clinical features and can be used for the diagnosis and prognosis of ovarian cancer. However, due to the heterogeneity and plasticity of CSCs, the determination of specific CSC phenotypes is difficult.
  • ||||||||||  ID119031166 / Ildong
    Intestine FXR agonist ID119031166 modulates ethanol and bile acid metabolism in ethanol-fed hamsters (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_1023;    
    In this study, the resistance of breast cancer to PTX was attributed to the existence of CSCs; ASIV weakened the resistance of MCF7-CSCs to PTX by significantly attenuating the hallmarks of breast cancer stemness and improved the efficacy of PTX. Our findings suggest that ID119031166 modulates ethanol and bile acid metabolism by regulating key metabolic genes in chronic ethanol exposure.
  • ||||||||||  Journal:  Altered Phenotypes of Breast Epithelial  (Pubmed Central) -  Dec 27, 2023   
    Similarly, only the M13HS-8 ZEB1-knock-out tumor hybrids showed a reduced invasion capacity. Although the ZEB1 knock-out resulted in only moderate phenotypic changes, our data support the role of ZEB1 in EMT and stemness.
  • ||||||||||  Journal:  Possible role of ALDH1 and CD44 in lip carcinogenesis. (Pubmed Central) -  Dec 21, 2023   
    In summary, although both ALDH1 and CD44 were associated with the presence of dysplasia in AC lesions, the present findings suggest that ALDH1 and CD44 may be activated by different etiopathogenic pathways, predominantly in distinct steps of oral carcinogenesis. CD44 would thus be more significantly related to the potentially malignant lesion, while ALDH1 would be closely linked to malignancy.
  • ||||||||||  Journal:  Hyaline protoplasmic astrocytopathy in epilepsy. (Pubmed Central) -  Dec 5, 2023   
    Filamin A labeled the inclusions but also labeled reactive astrocytes in a subset of patients. The immunoreactivity of the inclusions for various astrocytic markers and filamin A as well as the positivity of filamin A in reactive astrocytes raise the possibility that these astrocytic inclusions may be the result of an uncommon reactive or degenerative phenomenon.
  • ||||||||||  Journal:  Deep learning-based image (Pubmed Central) -  Nov 15, 2023   
    These neurons were negative for aldehyde dehydrogenase 1A1, with a lower co-expression rate for dopamine-D2-autoreceptors, but a ~7-fold higher likelihood of calbindin-d28k co-expression (~70%). These results have important implications, as DAT is crucial for dopamine
  • ||||||||||  Rizaben (tranilast) / Kissei, Nuon Therapeutics
    Journal, Cancer stem:  Cancer Stem Cells of Esophageal Adenocarcinoma are Suppressed by Inhibitors of TRPV2 and SLC12A2. (Pubmed Central) -  Nov 8, 2023   
    These findings shed light on the potential application of RSL3 in the treatment of glioblastoma relapse. Based on the present results, TRPV2 and SLC12A2 are involved in the maintenance of CSCs, and their specific inhibitors, tranilast and furosemide, respectively, have potential as targeted therapeutic agents for EAC.